Merck has created a cure for COVID-19. Is her stock going to skyrocket?

If approved, Merck & Co's drug could be the first CORONAVIRUS drug. However, some scientists fear side effects from it. figured it out

What does the company do

Industry : Pharmaceuticals
Ticker : MRK
Capitalization : $206.56 billion
P/E : 37.26
P/S : 4.30
Dividend yield : 3.13%
Oct 5 price : $81.6
Consensus Estimate : $94

Merck & Co is one of the world's leading pharmaceutical companies. Its main business is the creation and sale of medicines, vaccines, and animal HEALTH products.

The American company Merck & Co, or MSD, referred to in this article, is often confused with the German Merck. In 1891, Merck & Co was founded as a subsidiary of the German Merck group. In 1917, MSD was nationalized by the US , then privatized again in 1919 when George W. Merck bought back the shares. Since then they have been different companies.

In early October, Merck & Co announced that it had successfully tested a coronavirus drug. If approved, the drug may become the first in its class and even change the attitude towards the virus. We figured out what could prevent the triumph of Merck.